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Abstract: Background
Recent studies have demonstrated an association between high blood eosinophil
counts and greater risk of asthma exacerbations. We sought to determine whether
patients hospitalized for an asthma exacerbation were at greater risk of readmission if
they had a high blood eosinophil count documented before the first hospitalization.
Methods
This historical cohort study drew on 2 years of medical record data (Clinical Practice
Research Datalink with Hospital Episode Statistics linkage) of patients (aged ≥5 years)
admitted to hospital in England for asthma, with recorded blood eosinophil count within
1 baseline year before admission. We analyzed the association between high blood
eosinophil count (≥0.35x109 cells/L) and readmission risk during 1 year of follow-up
after hospital discharge, with adjustment for predefined, relevant confounders using
forward selection.
Results
We identified 2,613 eligible patients with asthma-related admission, of median age 51
years (interquartile range, 36-69) and 76% women (1,997/2,613). Overall, 835/2,613
(32.0%) had a preadmission high blood eosinophil count. During the follow-up year,
130/2,613 patients (5.0%) were readmitted for asthma, including 55/835 (6.6%) with vs.
75/1,778 (4.2%) without high blood eosinophil count at baseline (adjusted hazard ratio
[HR] 1.49; 95% CI 1.04-2.13, p=0.029). The association was strongest in never-
smokers (n=1,296; HR 2.16, 95% CI 1.27-3.68, p=0.005) and absent in current
smokers (n=547; HR 1.00, 95% CI 0.49-2.04, p=0.997).
Conclusions
A high blood eosinophil count in the year before an asthma-related hospitalization is
associated with increased risk of readmission within the following year. These findings
suggest that patients with asthma and preadmission high blood eosinophil count
require careful follow-up, with treatment optimization, after discharge.
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Abstract 23 
Background 24 
Recent studies have demonstrated an association between high blood eosinophil counts and 25 
greater risk of asthma exacerbations. We sought to determine whether patients hospitalized for 26 
an asthma exacerbation were at greater risk of readmission if they had a high blood eosinophil 27 
count documented before the first hospitalization. 28 
Methods 29 
This historical cohort study drew on 2 years of medical record data (Clinical Practice Research 30 
Datalink with Hospital Episode Statistics linkage) of patients (aged ≥5 years) admitted to 31 
hospital in England for asthma, with recorded blood eosinophil count within 1 baseline year 32 
before admission. We analyzed the association between high blood eosinophil count (≥0.35x109 33 
cells/L) and readmission risk during 1 year of follow-up after hospital discharge, with adjustment 34 
for predefined, relevant confounders using forward selection. 35 
Results 36 
We identified 2,613 eligible patients with asthma-related admission, of median age 51 years 37 
(interquartile range, 36-69) and 76% women (1,997/2,613). Overall, 835/2,613 (32.0%) had a 38 
preadmission high blood eosinophil count. During the follow-up year, 130/2,613 patients (5.0%) 39 
were readmitted for asthma, including 55/835 (6.6%) with vs. 75/1,778 (4.2%) without high 40 
blood eosinophil count at baseline (adjusted hazard ratio [HR] 1.49; 95% CI 1.04-2.13, p=0.029). 41 
The association was strongest in never-smokers (n=1,296; HR 2.16, 95% CI 1.27-3.68, p=0.005) 42 
and absent in current smokers (n=547; HR 1.00, 95% CI 0.49-2.04, p=0.997). 43 
Conclusions 44 
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A high blood eosinophil count in the year before an asthma-related hospitalization is associated with 45 
increased risk of readmission within the following year. These findings suggest that patients with asthma 46 
and preadmission high blood eosinophil count require careful follow-up, with treatment optimization, 47 
after discharge. 48 
 49 
Key words: asthma; eosinophils; patient readmission   50 
Kerkhof et al. 4 
Introduction 51 
Severe asthma exacerbations may result in hospital admissions, relatively rare but 52 
important events with adverse implications for patients’ quality of life, health care resource use, 53 
and related costs. Approximately 83,000 hospital episodes (including inpatient, day-case, and 54 
intensive care episodes) were recorded as related to asthma in England in 2011-2012, 55 
representing approximately 3.3 million patients with clinician-reported, diagnosed-and-treated 56 
asthma in England during that time [1].  57 
 Recent studies have demonstrated an association between high blood eosinophil counts 58 
and greater risk of asthma exacerbations, especially in patients with asthma that is not well-59 
controlled [2,3]. Moreover, among patients with severe asthma in a US cohort study, the odds of 60 
asthma-related hospital admissions were significantly greater for patients with high blood 61 
eosinophil count defined as ≥0.4x109 cells/L than for those with counts of <0.4x109 cells/L [4]. 62 
Similarly, in the UK, patients with severe uncontrolled eosinophilic asthma (blood eosinophil 63 
count ≥0.3x109 cells/L) experienced over 7 times the number of hospitalizations per year 64 
compared with the general asthma population [5], and in Finland, a blood eosinophil count 65 
>0.3x109 cells/L was associated with 13% greater rate of hospital admissions (vs. ≤0.3x109 66 
cells/L) among patients with asthma [6]. Targeted therapy for patients with severe eosinophilic 67 
asthma can reduce the rate of exacerbations requiring hospitalization and/or an emergency 68 
department (ED) visit [7,8].  69 
 Patients who are admitted to hospital for asthma-related reasons, such as a severe 70 
exacerbation, may be at risk of short-term readmission to hospital. For example, some patients 71 
with persistent airways inflammation are at risk of readmission after discharge despite treatment 72 
with corticosteroids [9,10]. Predictors of readmission are important to identify as this 73 
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information could be used to improve in-hospital and post-hospitalization patient management to 74 
minimize subsequent readmissions. Several demographic and socioeconomic risk factors for 75 
hospital readmissions have been reported for patients with asthma, including older age, greater 76 
number of comorbidities, an urban hospital setting, and longer length of hospital stay [11,12]. A 77 
recent study found that elevated blood eosinophil count (≥0.3x109 cells/L) in the first blood 78 
sample upon hospitalization was associated with a lower incidence of hospital readmissions as 79 
compared with an eosinophil count <0.3x109 cells/L [13]. Conversely, for patients with chronic 80 
obstructive pulmonary disease (COPD), a recent publication reports an association of increased 81 
readmissions with blood eosinophil count ≥0.20x109 cells/L at first hospitalization [14]. The 82 
variability in associations may be because blood eosinophils are prognostic and theragnostic.  83 
 The aim of this study was to determine if patients hospitalized for an asthma exacerbation 84 
were more likely to be readmitted if their preadmission blood eosinophil count was elevated. Our 85 
hypothesis was that standard management of asthma exacerbations is insufficient to prevent 86 
readmissions for patients who have high blood eosinophil counts in the year preceding a 87 
hospitalization.  88 
 89 
Methods 90 
Data source 91 
We used primary and secondary care data from the Clinical Practice Research Datalink 92 
(CPRD) and linked Hospital Episode Statistics (HES) for this historical cohort study of patients 93 
with asthma who had been admitted to hospital in England. The CPRD is a large well-validated 94 
database, frequently used for medical and health research, that contains de-identified, 95 
longitudinal medical records of 5 million patients from >600 UK practices [15]. The linked HES 96 
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data include detailed information about hospital admissions, ED visits, and outpatient visits to 97 
secondary care in England [16]. We used the HES Admitted Patient Care database, which 98 
contains records of patients who were admitted to a hospital ward, including patients who visited 99 
an ED before admission and those who were admitted to an intensive care unit. Diagnostic and 100 
treatment data are recorded in the CPRD using Read codes, while diagnosis data are recorded in 101 
HES using International Classification of Disease (ICD)-10 clinical coding and OPCS4 102 
procedural coding.  103 
 The study dataset spanned the period from April 1997 through February 2016. 104 
 105 
Study design and patients 106 
Eligible patients were 5 years or older at the time of their most recent asthma diagnosis 107 
and had active asthma, which we defined as (1) a diagnostic Read code for asthma qualifying for 108 
inclusion in the asthma registry, which general practices in the UK maintain for the Quality 109 
Outcomes Framework (QOF) [17], (2) no recorded asthma-resolved Read code after the last 110 
asthma diagnosis code, and (3) at least 2 prescriptions for asthma (controller or reliever 111 
medication) during 1 baseline year. Patients admitted to hospital with asthma as the primary 112 
diagnosis (ICD-10 code J45-J46) were eligible for the study if they had one or more valid blood 113 
eosinophil counts recorded during the year before the hospital admission with no prescription for 114 
oral corticosteroids within 2 weeks before the eosinophil count. 115 
 Eligible patients had to have available, continuous data throughout the study period (Fig 116 
1), which included ≥1 baseline year before discharge from the hospital for patient 117 
characterization and ≥1 outcome year after hospital discharge for follow-up (except for patients 118 
who died within 1 year after hospital discharge). We included the first hospitalization recorded 119 
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for each patient meeting those criteria. A diagnostic Read code for any of the following chronic 120 
respiratory conditions recorded at any time was cause for exclusion from the study: 121 
bronchiectasis, pulmonary sarcoidosis, hypersensitivity pneumonitis, malignancy of the lungs, 122 
interstitial lung disease, and cystic fibrosis. Patients with concomitant diagnosis of COPD were 123 
not excluded. 124 
 125 
Fig 1. Study Design. 126 
 127 
 The study was performed in compliance with all applicable local and international laws 128 
and regulations and to standards suggested for observational studies, including an independent 129 
advisory group, use of an a priori analysis plan, and study registration with commitment to 130 
publish [18]. The study protocol was approved by the CPRD Independent Scientific Advisory 131 
Committee (ISAC approval number 16_236) and registered with the European Union electronic 132 
Register of Post-Authorisation Studies (EU PAS Register number EUPAS15869) [19]. No 133 
patient identifying information was accessible during the study. 134 
 135 
Outcome assessments 136 
The exposure of interest was the most recent blood eosinophil count measured within 1 137 
year before hospital admission. For patients who had multiple tests in the baseline year, we used 138 
the blood eosinophil count (with no oral corticosteroid prescription within 2 weeks prior) that 139 
was closest to the admission. A high blood eosinophil count was defined as ≥0.35x109 cells/L (or 140 
≥0.4x109 cells/L when counts were recorded to only 1 decimal place). This value was chosen 141 
based on our findings in a prior study in which patients with blood eosinophil counts >0.3x109 142 
cells/L experienced more severe exacerbations and poorer asthma control [3]. 143 
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 The primary outcome was readmission to hospital with asthma as primary diagnosis 144 
(ICD-10 code J45/J46) over a 4-week outcome period and over a 1-year outcome period after 145 
discharge from the hospital (Fig 1). The secondary outcome was readmission to hospital with 146 
asthma as a secondary/subsidiary diagnosis and a respiratory condition as primary diagnosis 147 
(ICD-10 codes J00-J99), again observed over 4 weeks and 1 year. 148 
 149 
Statistical analysis 150 
Patients’ baseline characteristics and hospital readmissions were compared between 151 
patients with high and normal blood eosinophil counts using Pearson's χ2 test of independent 152 
categories for categorical variables, and the Mann-Whitney test for continuous variables.  153 
 Kaplan-Meier curves were constructed for patients with and without high blood 154 
eosinophil count for the maximum follow-up period of 1 year after hospital discharge. 155 
Comparisons were made with log-rank analyses, and patients were censored if they died.  156 
Cox proportional hazard regression, with the time from hospital discharge date to the first 157 
readmission date as the “survival” time, was performed to estimate hazard ratios (HRs) with 95% 158 
confidence intervals (CIs) for the association between high blood eosinophil count and time to 159 
readmission, adjusted for potential confounders. The following variables were evaluated for their 160 
potential confounding effect on the effect estimate: sex, age, body mass index (BMI), smoking 161 
habits, timing of blood eosinophil count relative to the first hospitalization, Charlson comorbidity 162 
index (categorical as 0, 1−4, ≥5), comorbidities, and Global Initiative for Asthma [20] (GINA) 163 
treatment step (S1 Table). The likelihood of a blood eosinophil count being recorded was greater 164 
at dates closer to the hospital admission, and we included the time between recorded eosinophil 165 
count and first hospitalization as a confounder in the Cox regression model. Final models were 166 
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arrived at following a forward-selection procedure, in which variables were added one-by-one 167 
and retained if the coefficient for the effect estimate (high eosinophil count) changed by ≥5%. 168 
Co-linearity was checked by evaluating variance inflation factors, which were all under 5%. The 169 
validity of the proportional hazards assumption was checked by examination of survival curves, 170 
and p-values were calculated using a Wald test. 171 
 Potential effect modification of smoking status was tested for significance by including 172 
an interaction term into the full model. We conducted several sensitivity analyses, repeating the 173 
outcome analyses using alternative definitions of high blood eosinophil counts (≥0.25x109 174 
cells/L or ≥0.3x109 cells/L if rounded, and ≥0.45x109 cells/L or ≥0.5x109 cells/L if rounded) and 175 
examining outcomes in two subsets of patients: (1) after exclusion of those who initiated inhaled 176 
corticosteroids (ICS) after their first asthma-related hospital admission and (2) after exclusion of 177 
patients with a concomitant diagnosis of COPD. 178 
 Statistical analyses were conducted using IBM SPSS Statistics version 23 (IBM SPSS 179 
Statistics, Feltham, Middlesex, UK) and R version 3.0.2 (The R Project for Statistical 180 




Of 146,485 patients in the CPRD with HES data linkage, 22,940 (16%) patients had at 185 
least one hospital admission for asthma and ≥2 years of medical record data, and 3,611 patients 186 
(16%) of those hospitalized had an eosinophil count recorded within 1 year before the 187 
hospitalization (and no oral corticosteroid prescription within 2 weeks prior). Of these 3,611 188 
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patients, 2,613 patients (72%) were ≥5 years old, had active asthma, and were eligible for the 189 
study (Fig 2).  190 
 191 
Fig 2. Flow Diagram Showing Selection of Eligible Patients from the Database. 192 
CPRD = Clinical Practice Research Database. HES = Hospital Episode Statistics. OCS = oral 193 
corticosteroid. QOF = Quality Outcomes Framework. 194 
 195 
 In the study population, 482 of 2,613 patients (18%) were discharged from hospital on 196 
the same day. Six patients died (one patient died 31 weeks after readmission for asthma and was 197 
not censored; others were censored) during 1 year of follow up. 198 
 Characteristics of the total population with blood eosinophil count (n=2,613) and 13,016 199 
patients with asthma who met all eligibility criteria except availability of blood eosinophil count 200 
during baseline are presented in S2 Table. There were multiple statistically significant 201 
differences between the two groups of patients. Eligible patients with recorded eosinophil count 202 
were older than the 13,016 patients without eosinophil count (median age, 50 vs. 33 years), more 203 
commonly female (1,997/2,613, 76% vs. 7,542/13,016, 58%), heavier (mean BMI 29.1 vs. 26.0 204 
kg/m2), and receiving a higher median ICS dose (219 vs. 132 µg/day, fluticasone-propionate 205 
equivalent) during the baseline year (S2 Table). 206 
 A high blood eosinophil count (≥0.35x109 cells/L) was recorded during the year before 207 
the hospital admission for 835 of 2,613 patients (32%). The high blood eosinophil cohort had a 208 
median age of 45 (vs. 54 years in the cohort with eosinophil count of <0.35x109 cells/L) and 209 
included proportionately fewer women and fewer overweight and obese patients (Table 1). In 210 
addition, patients with eosinophil count ≥0.35x109 cells/L were more likely to be never-smokers 211 
and to have a recorded diagnosis of rhinitis, atopic eczema, or nasal polyps. 212 
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Table 1. Baseline Demographic and Clinical Characteristics. 215 
 
All patients 
(N = 2,613) 
Blood eosinophil cohort  
Variable 
<0.35x109 cells/L 
(n = 1,778) 
≥0.35x109 cells/L 
(n = 835) 
P valuea 
Age     
Median (IQR) 51.0 (36.0-69.0) 54.0 (39.0-70.3) 45.0 (30.0-65.0) <0.0001 
5-12 years 56 (2.1) 17 (1.0) 39 (4.7) <0.0001 
13-17 years 77 (2.9) 31 (1.7) 46 (5.5) 
18-64 years 1,681 (64.3) 1,141 (64.2) 540 (64.7) 
≥65 years 799 (30.6) 589 (33.1) 210 (25.1) 
Female sex  1,997 (75.7) 1,392 (78.3) 585 (70.1) <0.0001 
Smoking statusb      
Data available 2,597 (99.4) 1,771 (99.6) 826 (98.9)  
Current smoker 547 (21.1) 378 (21.3) 169 (20.5) 0.007 
Ex-smoker 754 (29.0) 544 (30.7) 210 (25.4) 
Never smoker 1,296 (49.9) 849 (47.9) 447 (54.1) 
Body mass indexb     
Data available 2,260 (86.5) 1,551 (87.2) 709 (84.9)  
Mean (SD) 29.2 (7.0) 29.6 (7.0) 28.4 (7.0) <0.0001 
<18.5 kg/m2 78 (3.5) 38 (2.5) 40 (5.6) <0.0001 
≥18.5 kg/m2 to <25 kg/m2 625 (27.7) 393 (25.3) 232 (32.7) 
≥25 kg/m2 to <30 kg/m2  625 (27.7) 450 (29.0) 175 (24.7) 
≥30 kg/m2  932 (41.2) 670 (43.2) 262 (37.0) 
Allergic/non-allergic rhinitisc 876 (33.5) 545 (30.7) 331 (39.6) <0.0001 
Atopic eczemac 927 (35.5) 595 (33.5) 332 (39.8) <0.0001 
Nasal polypsc 83 (3.2) 39 (2.2) 44 (5.3) <0.0001 
Chronic rhinosinusitisc 579 (22.2) 400 (22.5) 179 (21.4) 0.54 
COPDc 284 (10.9) 192 (10.8) 92 (11.0) 0.87 
GERDc 474 (18.1) 355 (20.0) 119 (14.3) <0.001 
Cardiovascular diseasec 654 (25.0) 491 (27.6) 163 (19.5) <0.0001 
Charlson comorbidity index     
0 611 (23.4) 429 (24.1) 182 (21.8) 0.028 
1-4 1,661 (63.6) 1,101 (61.9) 560 (67.1) 
≥5 341 (13.1) 248 (13.9) 93 (11.1) 
GINA step of asthma treatmentb     
1 124 (4.7) 78 (4.4) 46 (5.5) 0.009 
2 493 (18.9) 357 (20.1) 136 (16.3) 
3 468 (17.9) 298 (16.8) 170 (20.4) 
4 1,220 (46.7) 848 (47.7) 372 (44.6) 
5 308 (11.8) 197 (11.1) 111 (13.3) 
≥1 ICS inhaler prescribed 2,444 (93.5) 1,671 (94.0) 773 (92.6) 0.173 
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Daily dose of ICS (µg/day), 
median (IQR)d 
262 (110-521) 263 (110-534) 247 (99-492) 0.041 
≥1 SABA inhaler prescribed 2,432 (93.1) 1,646 (92.6) 786 (94.1) 0.144 
Daily SABA dose, median (IQR)d 1.64 (0.82-3.55) 1.64 (0.66-3.29) 2.04 (0.82-4.11) <0.0001 
OCS daily dose (g), median (IQR) 0.55 (0-1.64) 0.55 (0-1.56) 0.55 (0-1.75) 0.139 
No. severe asthma exacerbations     
0 747 (28.6) 516 (29.0) 231 (27.7) 0.25 
1 848 (32.5) 589 (33.1) 259 (31.0) 
2 506 (19.4) 345 (19.4) 161 (19.3) 
3 266 (10.2) 174 (9.8) 92 (11.0) 
≥4 246 (9.4) 154 (8.7) 92 (11.0) 
Data expressed as No. (%) unless otherwise noted. COPD = chronic obstructive pulmonary disease. GERD = 216 
gastroesophageal reflux disease. GINA = Global Initiative for Asthma; ICS = inhaled corticosteroid; OCS = oral 217 
corticosteroid; SABA = short-acting β-agonist.  218 
aP-value comparing blood eosinophil cohorts, computed from χ2 test for categorical variables, or Mann-Whitney test, 219 
for continuous variables. Where variables are presented as both continuous and categorical, the p-value is from the 220 
Mann-Whitney test. 221 
bThe closest BMI within 10 years of hospital discharge, and the smoking status closest to and within 5 years before 222 
hospital discharge, were included. The GINA treatment step was determined based on the last prescription before 223 
the hospitalization (S1 Table). The BMI categories applied to patients ≥18 years old; for children, BMI was not 224 
calculated because accurate information on age in months required to calculate BMI z-scores was not provided for 225 
privacy reasons. 226 
cComorbidities were those with diagnostic Read code ever-recorded in the available data before hospital discharge. 227 
dICS dose expressed as fluticasone propionate equivalent (µg/day), and one SABA dose defined as 200 µg in 228 
albuterol equivalents. 229 
 230 
 231 
The likelihood of a blood eosinophil count being recorded was greater at dates closer to 232 
the hospital admission (S1 Fig). Patients with measurements within 4 weeks before the 233 
hospitalization were more likely to have a high blood eosinophil count (128/339, 38%) than 234 
those with measurement within a longer time period before the hospitalization (707/2274, 31%; 235 
p=0.014). The length of time between recorded eosinophil count and admission with asthma as 236 
the primary diagnosis was greater in patients with high blood eosinophil counts than in patients 237 
without high counts, but the difference in distribution was not statistically significant (144 days 238 
[IQR, 56−250] vs. 131 days [58−229], p=0.159). 239 
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The median duration of hospitalization (2 nights) was the same in patients with and 240 
without a high blood eosinophil count; however, there were fewer patients with a high blood 241 
eosinophil count who had a long hospital stay (Table 2). 242 
 243 
Table 2. Duration of Hospitalization. 244 
 
All patients 
(N = 2,613) 
Blood eosinophil cohort  
Variable 
<0.35x109 cells/L 
(n = 1,778) 
≥0.35x109 
cells/L 
(n = 835) 
P valuea 
Nights in hospital, median (IQR)  2 (1–5) 2 (1–4)  
No. nights in hospital, n (%)     
0 482 (18.4) 323 (18.2) 159 (19.0) 0.006 
1 529 (20.2) 349 (19.6) 180 (21.6) 
2 356 (13.6) 230 (12.9) 126 (15.1) 
3 281 (10.8) 182 (10.2) 99 (11.9) 
4 243 (9.3) 162 (9.1) 81 (9.7) 
5 149 (5.7) 99 (5.6) 50 (6.0) 
6 142 (5.4) 106 (6.0) 36 (4.3) 
≥7 431 (16.5) 327 (18.4) 104 (12.5) 
aP-value comparing blood eosinophil cohorts computed from χ2 test. 245 
 246 
Readmissions by eosinophil cohort 247 
Only 6 patients were readmitted to the hospital within 4 weeks of the first admission, 248 
with no significant difference between blood eosinophil cohorts (Table 3). At 1 year, 130 of 249 
2,613 (5%) patients overall were readmitted for asthma, including a significantly greater 250 
percentage of patients with high vs. normal blood eosinophil count (Table 3; Fig 3). Patients with 251 
eosinophil count of ≥0.35x109 cells/L had a 49% higher adjusted risk of readmission to hospital 252 
for asthma in the first year of follow-up than patients without a high count (HR 1.49; 95% CI 253 
1.04–2.13; p=0.029; Table 3). 254 
 255 
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Table 3. Readmissions to Hospital within 4 Weeks and 1 Year and Hazard Ratios for 256 
Readmission in the High Eosinophil Count Cohort. 257 





(n = 1,778) 
≥0.35x109 
cells/L 
(n = 835) 
P valuea 
Adjusted HR (95% 




With asthma as primary diagnosis 
(n = 2,613) 
   
  
Within 4 weeks 4 (0.2) 2 (0.2) 0.94 -- -- 
Within 1 year 75 (4.2) 55 (6.6) 0.009 1.49 (1.04-2.13) 0.029 
By known smoking status (n 
= 2,597)c 
     
Never-smokers (n = 1,296) 29 (3.4) 30 (6.7) 0.007 2.16 (1.27-3.68) 0.005 
Ex-smokers (n = 754) 19 (3.5) 13 (6.2) 0.010 1.49 (0.73-3.06) 0.27 
Current smokers (n = 547) 27 (7.1) 12 (7.1) 0.99 1.00 (0.49-2.04) 0.997 
Never/ex-smokers pooled (n 
= 2,050) 
48 (3.4) 43 (6.5) 0.002 1.78 (1.17-2.73) 0.007 
With respiratory condition other 
than asthma, and asthma as 
subsidiary diagnosis (n = 2,613) 
     
Within 4 weeks 22 (1.2) 8 (1.0) 0.53 -- -- 
Within 1 year 81 (4.6) 39 (4.7) 0.90 1.12 (0.76-1.65) 0.57 
aP-value computed using χ2 test. 258 
bAdjusted for sex, age, smoking status, timing of blood eosinophil count measurement, duration of index 259 
hospitalization. 260 
c16 patients with no recent record of smoking status were excluded from the analyses by smoking status.  261 
 262 
 263 
Fig 3. Kaplan-Meier Curves Describing the Cumulative “Survival” of a Readmission to 264 
Hospital for Asthma in the First Year After an Admission with Asthma as the Primary 265 
Diagnosis in Patients With and Without High Blood Eosinophil Count. 266 
 267 
Interaction with smoking status 268 
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The effect of current smoking was non-significant (p=0.073) when tested by including an 269 
interaction term for current smoking (yes/no) and high blood eosinophil count (yes/no) into the 270 
model. The increased readmission rate with a high blood eosinophil count was found only in 271 
non-smokers (HR 1.84; 1.20–2.80; p=0.005) and not in current smokers (HR 0.88; 0.44–1.76; 272 
p=0.73). In this analysis of all 2,613 patients, 16 patients without recent, recorded smoking status 273 
were included as non-smokers (never-smokers plus ex-smokers).  274 
 Results were similar for patients with known smoking status, with a significant 216% 275 
higher adjusted risk of readmission for never-smokers with high blood eosinophil count, and no 276 
additional risk for current smokers with high blood eosinophil count (Table 3). Although the 277 
association was most pronounced in never-smokers, no significant difference in the association 278 
was found between never-smokers and ex-smokers (p=0.67) in the 2,050 patients recorded as not 279 
currently smoking.  280 
 281 
Sensitivity analyses 282 
 A high blood eosinophil count was recorded for 1,328 patients (51%) when defined as 283 
≥0.25x109 cells/L, and for 588 patients (23%) when defined as ≥0.45x109 cells/L. The 284 
association between a high blood eosinophil count and readmission to hospital for asthma was 285 
less pronounced and not significant for patients with blood eosinophil count of either ≥0.25x109 286 
cells/L (HR=1.17; 0.82−1.66; p=0.39) or ≥0.45x109 cells/L (HR=1.15; 0.77−1.72; p=0.50; S3 287 
Table). The association was also not significant in never-smokers or in never/ex-smokers 288 
combined using either definition of high blood eosinophil count (S3 Table). 289 
 A total of 169 of the 2,613 patients (6%) had no prescription for ICS in the baseline year 290 
before being hospitalized for asthma; of the 169, 115 (68%) had ICS prescribed in the outcome 291 
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year. After exclusion of these 115 patients, HRs for the association with blood eosinophil count 292 
of ≥0.35x109 cells/L slightly increased as compared with those for the full population (S3 Table). 293 
The HR was 1.77 (95% CI, 1.15−2.72; p=0.009) for never/ex-smokers combined, which was 294 
very similar to the HR for never/ex-smokers combined of the full population (1.78). However, 295 
effect modification by current smokers was not significant in this subpopulation (p=0.28). 296 
 Results of an additional subanalysis excluding patients with a concomitant diagnosis of 297 
COPD showed no relevant difference in association for the remaining 2,329 patients (HR= 1.48; 298 
95% CI 1.01–2.17, p=0.045; see S3 Table). 299 
 300 
Discussion 301 
In this large, historical cohort study, we found that patients who had a blood eosinophil 302 
count of ≥0.35x109 cells/L recorded in the year preceding an asthma-related hospitalization had a 303 
significantly greater risk of readmission for asthma during the year after they were discharged. 304 
Few patients (n=6) were readmitted to hospital for asthma within 4 weeks after discharge, while 305 
by 1 year after discharge, 5% (130 of 2,613) patients were readmitted for asthma. The greater 306 
risk of readmission during 1 year follow-up was present only for patients with high blood 307 
eosinophil count who were never- or ex-smokers (not for current smokers). 308 
 Our study is one of few studies examining hospital readmissions for asthma in a general 309 
asthma population and in the real-life setting. Readmissions in the present study were 310 
comparatively infrequent relative to results in other studies: for example, in one US study, 311 
approximately 4% of patients were readmitted for an asthma exacerbation within 30 days [21], 312 
and in France from 2002–2005, 15% were readmitted for asthma within 1 year [22]. The overall 313 
Kerkhof et al. 18 
rate of hospital admissions for asthma in England appears to be lower that than for Western 314 
Europe as a whole, the latter reported in 2004 to be 7% [1,23]. 315 
Other recent studies of hospital readmissions have been limited to patients on systemic 316 
corticosteroids [9], have examined readmissions up to only 30 days [11,12,24], were much 317 
smaller [24], and/or were conducted at a single institution [25,26]. None of these studies, nor 318 
others examining readmissions after 30 days [27-29], examined the association of hospital 319 
readmissions with blood eosinophil count. While Gonzalez-Barcala et al. [13] in their 320 
retrospective study at a single hospital in Spain found differently from the present study that 321 
elevated eosinophil count was associated with a lower incidence of readmissions, it is difficult to 322 
compare their study with ours because of differences in methods. For example, the reference 323 
blood eosinophil count was that taken upon admission rather than before hospitalization during a 324 
baseline year, and the length of the follow-up period for analyzing readmissions is unclear [13].  325 
 An interesting finding in the present study that requires further investigation is the effect 326 
of smoking status on association of readmissions with eosinophil count. Cigarette smoking 327 
increases levels of oxidative stress, alters airway immune responses, and increases risk of 328 
hospitalization in patients with asthma [30]. Westerhof et al. [31] in their study of patients with 329 
severe asthma found that frequent exacerbations were associated with blood eosinophil count 330 
only in never smokers and not in ex-smokers, for whom blood neutrophil count was an 331 
independent predictor of frequent exacerbations (smokers not studied). In our study, both never- 332 
and ex-smokers (but not current smokers) who had a high eosinophil count were at greater risk of 333 
asthma-related readmission, although for ex-smokers separately this association was not 334 
statistically significant. Moreover, in our study the difference in association between non-335 
smokers (never-plus ex-smokers pooled) and smokers was large and statistically significant. 336 
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Clearly, additional work is needed to examine biomarker and peripheral blood cell profiles in 337 
relation to smoking status and hospital readmissions and other asthma-related outcomes. 338 
 The median duration of hospitalization (2 nights) was the same in both normal and high 339 
blood eosinophil cohorts; however, patients with a high blood eosinophil count were less likely 340 
to have a hospital stay longer than 5 nights (17% vs. 24% of those without high eosinophil 341 
count). This finding illustrates the conundrum of eosinophilic asthma: while it tends to be more 342 
severe in terms of exacerbations and asthma control, eosinophilic asthma is also potentially more 343 
responsive to therapies targeting type 2 inflammation, including ICS and biologics. 344 
 We speculated that the association between eosinophil count and readmission could be 345 
diluted for patients with eosinophil count performed several months before the first admission; 346 
therefore, we re-examined outcomes including only patients with eosinophil counts measured 347 
close to the initial hospitalization to see if the association were stronger. However, when 348 
selecting those with eosinophil count recorded within 4 months before hospitalization, the 349 
numbers became small and associations non-significant, although the direction of the effect was 350 
the same: for never- and ex-smokers pooled (n=915), the risk of readmission was 51% greater 351 
but non-significant (adjusted HR 1.69;0.60–4.76; p=0.32). 352 
 A strength of this study is that we included a broad patient population with asthma, not 353 
limited to those with severe asthma. We selected inclusion criteria to ensure that patients’ asthma 354 
was actively managed in advance of the hospital admission, thereby excluding patients 355 
experiencing a first episode of asthma diagnosed at the time of admission. Moreover, we 356 
required that patients had not received an oral corticosteroid prescription within 2 weeks before 357 
the eosinophil count to obviate the eosinopenic effects of systemic corticosteroids [32,33]. The 358 
data sources we used are well-regarded and frequently employed for pharmacoepidemiological 359 
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studies [15-17,34]. The primary care data in the CPRD is considered to be high-quality, with 360 
recording that has been standardized and improved since the institution in 2004 of the UK 361 
Quality Outcomes Framework (QOF) [17], which provides financial incentives for GPs to 362 
deliver quality care, including an annual asthma review covering asthma control status, smoking, 363 
and inhaler technique. Detailed information about hospital admissions was drawn from HES, a 364 
data warehouse linked to the CPRD [16].  365 
Nevertheless, a limitation is that the study dataset comprised information collected for 366 
clinical and routine use rather than specifically for research purposes. Moreover, prescriptions 367 
for drugs prescribed by specialists are not reliably recorded in the CPRD. Therefore, we could 368 
not evaluate treatment prescribed immediately after hospital discharge. However, the daily dose 369 
of ICS prescribed by GPs in the year after admission was not significantly different between 370 
patients with and without high eosinophil counts (median for both: 329 vs. 329 µg/day 371 
fluticasone-equivalent, p=0.70, Mann-Whitney test). Finally, as for all observational studies, 372 
there is the possibility of residual confounding from unrecognized and/or unmeasured factors. 373 
 A “count-response” association of blood eosinophil levels with risk of asthma 374 
exacerbations has been reported in both an observational study [3] and for the placebo arm of 375 
clinical trials [35,36]. Our study had insufficient patient numbers to assess the presence of a 376 
count-response relationship with hospital readmissions using incremental categories to define 377 
high eosinophil count. Our definition of ≥0.35x109 cells/L for high blood eosinophil count 378 
captured a clear association of high blood eosinophil count with risk of readmission, while there 379 
were fewer patients, hence limited statistical power, to evaluate the higher cut-point of ≥0.45x109 380 
cells/L, although the direction of the effect was the same. Alternatively, new ICS use or better 381 
ICS adherence after the index hospitalization might have reduced the effect of elevated 382 
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eosinophil count; however, it would not be easy to quantify this possibility in the framework of a 383 
historical cohort study, and in spite of this possibility we found a strong association at the 384 
≥0.35x109 cells/L definition.  385 
We did not exclude patients with a concomitant diagnosis of COPD; therefore, 386 
approximately one-tenth of the study population appeared to have some form of physician-387 
diagnosed asthma-COPD overlap [37], although these patients were too few to analyze 388 
separately. However, the sensitivity analysis excluding these patients supported the findings for 389 
the full population. 390 
 By necessity we were able to include only patients who had a recorded blood eosinophil 391 
count, which is not routinely measured in clinical practice, a factor serving as a possible source 392 
of selection bias and thereby limiting the generalizability of our findings. There were large 393 
differences in baseline characteristics between the patients with available eosinophil count and 394 
those without, who tended to be younger; more likely female, a current smoker, and of normal 395 
weight; and less likely having comorbidities such as rhinitis, chronic sinusitis, gastroesophageal 396 
reflux disease, and cardiovascular disease. The age differences were expected because older 397 
people more frequently have full blood counts available. Further work is needed to examine the 398 
use of blood eosinophil count in the clinical assessment of the full spectrum of patients with 399 
asthma.  400 
 Tailoring asthma therapy using sputum eosinophil counts appears to be effective in 401 
reducing exacerbations, particularly for adults with frequent exacerbations [38]. Thus, blood 402 
eosinophil count, more practical to measure than sputum eosinophil count, could play a role in 403 
tailoring asthma therapy with the goal of reducing exacerbations, hence potentially hospital 404 
readmissions. Moreover, further research is needed to identify the mechanism(s) behind the 405 
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increased risk of readmission associated with high blood eosinophil count, such as possible 406 
undertreatment with ICS or insufficient effectiveness of ICS. In addition, more specifically, a re-407 
examination is needed of the absence of association with readmissions and high blood eosinophil 408 
count in current smokers, as there was limited statistical power in this subgroup of patients, 409 
reflected by the wide confidence interval. 410 
 411 
Conclusions  412 
A high blood eosinophil count in the year before an asthma-related hospitalization is 413 
associated with increased risk of readmission within the following year. This risk was slightly 414 
greater in the subset of patients who were not new initiators of ICS treatment after their index 415 
hospital admission, suggesting that this trait is only partially treatable with anti-inflammatory 416 
therapy. This association was present only in non-smoking patients with high blood eosinophil 417 
count. Our findings support the benefit of including a full blood count with differential as a 418 
routine assessment in clinical practice for patients with not well-controlled asthma. Moreover, 419 
our findings support the need for careful follow-up, with treatment optimization, after hospital 420 
discharge for patients with asthma and preadmission high blood eosinophil count. 421 
  422 
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Abstract 23 
Background 24 
Recent studies have demonstrated an association between high blood eosinophil counts and 25 
greater risk of asthma exacerbations. We sought to determine whether patients hospitalized for 26 
an asthma exacerbation were at greater risk of readmission if they had a high blood eosinophil 27 
count documented before the first hospitalization. 28 
Methods 29 
This historical cohort study drew on 2 years of medical record data (Clinical Practice Research 30 
Datalink with Hospital Episode Statistics linkage) of patients (aged ≥5 years) admitted to 31 
hospital in England for asthma, with recorded blood eosinophil count within 1 baseline year 32 
before admission. We analyzed the association between high blood eosinophil count (≥0.35x109 33 
cells/L) and readmission risk during 1 year of follow-up after hospital discharge, with adjustment 34 
for predefined, relevant confounders using forward selection. 35 
Results 36 
We identified 2,613 eligible patients with asthma-related admission, of median age 51 years 37 
(interquartile range, 36-69) and 76% women (1,997/2,613). Overall, 835/2,613 (32.0%) had a 38 
preadmission high blood eosinophil count. During the follow-up year, 130/2,613 patients (5.0%) 39 
were readmitted for asthma, including 55/835 (6.6%) with vs. 75/1,778 (4.2%) without high 40 
blood eosinophil count at baseline (adjusted hazard ratio [HR] 1.451.49; 95% CI 1.0204-2.0813, 41 
p=0.040029). The association was strongest in never-smokers (n=1,296; HR 1.952.16, 95% CI 42 
1.161.27-3.313.68, p=0.013005) and absent in current smokers (n=547; HR 0.971.00, 95% CI 43 
0.4849-1.972.04, p=0.94997). 44 
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Conclusions 45 
A high blood eosinophil count in the year before an asthma-related hospitalization is associated with 46 
increased risk of readmission within the following year. These findings suggest that patients with asthma 47 
and preadmission high blood eosinophil count require careful follow-up, with treatment optimization, 48 
after discharge. 49 
 50 
Key words: asthma; eosinophils; patient readmission   51 
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Introduction 52 
Severe asthma exacerbations may result in hospital admissions, relatively rare but 53 
important events with adverse implications for patients’ quality of life, health care resource use, 54 
and related costs. Approximately 83,000 hospital episodes (including inpatient, day-case, and 55 
intensive care episodes) were recorded as related to asthma in England in 2011-2012, 56 
representing approximately 3.3 million patients with clinician-reported, diagnosed-and-treated 57 
asthma in England during that time [1].  58 
 Recent studies have demonstrated an association between high blood eosinophil counts 59 
and greater risk of asthma exacerbations, especially in patients with asthma that is not well-60 
controlled [2,3]. Moreover, among patients with severe asthma in a US cohort study, the odds of 61 
asthma-related hospital admissions were significantly greater for patients with high blood 62 
eosinophil count defined as ≥0.4x109 cells/L than for those with counts of <0.4x109 cells/L [4]. 63 
Similarly, in the UK, patients with severe uncontrolled eosinophilic asthma (blood eosinophil 64 
count ≥0.3x109 cells/L) experienced over 7 times the number of hospitalizations per year 65 
compared with the general asthma population [5], and in Finland, a blood eosinophil count 66 
>0.3x109 cells/L was associated with 13% greater rate of hospital admissions (vs. ≤0.3x109 67 
cells/L) among patients with asthma [6]. Targeted therapy for patients with severe eosinophilic 68 
asthma can reduce the rate of exacerbations requiring hospitalization and/or an emergency 69 
department (ED) visit [6,77,8].  70 
 Patients who are admitted to hospital for asthma-related reasons, such as a severe 71 
exacerbation, may be at risk of short-term readmission to hospital. For example, some patients 72 
with persistent airways inflammation are at risk of readmission after discharge despite treatment 73 
with corticosteroids [8,99,10]. Predictors of readmission are important to identify as this 74 
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information could be used to improve in-hospital and post-hospitalization patient management to 75 
minimize subsequent readmissions. While sSeveral demographic and socioeconomic risk factors 76 
for hospital readmissions have been reported for patients with asthma, including older age, 77 
greater number of comorbidities, an urban hospital setting, and longer length of hospital stay 78 
[10,1111,12]. A recent study found that, the association between elevated blood eosinophil count 79 
and (≥0.3x109 cells/L) in the first blood sample upon hospitalization was associated with a lower 80 
incidence of hospital readmissions as compared with an eosinophil count <0.3x109 cells/L 81 
[13].has not been examined for a general asthma population. For Conversely, for patients with 82 
chronic obstructive pulmonary disease (COPD), a recent publication reports an association of 83 
increased readmissions with blood eosinophil count ≥0.20x109 cells/L at first hospitalization 84 
[1214]. The variability in associations may be because blood eosinophils are prognostic and 85 
theragnostic.  86 
 The aim of this study was to determine if patients hospitalized for an asthma exacerbation 87 
were more likely to be readmitted if their preadmission blood eosinophil count was elevated. Our 88 
hypothesis was that standard management of asthma exacerbations is insufficient to prevent 89 
readmissions for patients who have high blood eosinophil counts in the year preceding a 90 
hospitalization.  91 
 92 
Methods 93 
Data source 94 
We used primary and secondary care data from the Clinical Practice Research Datalink 95 
(CPRD) and linked Hospital Episode Statistics (HES) for this historical cohort study of patients 96 
with asthma who had been admitted to hospital in England. The CPRD is a large well-validated 97 
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database, frequently used for medical and health research, that contains de-identified, 98 
longitudinal medical records of 5 million patients from >600 UK practices [1315]. The linked 99 
HES data include detailed information about hospital admissions, ED visits, and outpatient visits 100 
to secondary care in England [1416]. We used the HES Admitted Patient Care database, which 101 
contains records of patients who were admitted to a hospital ward, including patients who visited 102 
an ED before admission and those who were admitted to an intensive care unit. Diagnostic and 103 
treatment data are recorded in the CPRD using Read codes, while diagnosis data are recorded in 104 
HES using International Classification of Disease (ICD)-10 clinical coding and OPCS4 105 
procedural coding.  106 
 The study dataset spanned the period from April 1997 through February 2016. 107 
 108 
Study design and patients 109 
Eligible patients were 5 years or older at the time of their most recent asthma diagnosis 110 
and had active asthma, which we defined as (1) a diagnostic Read code for asthma qualifying for 111 
inclusion in the asthma registry, which general practices in the UK maintain for the Quality 112 
Outcomes Framework (QOF) [1517], (2) no recorded asthma-resolved Read code after the last 113 
asthma diagnosis code, and (3) at least 2 prescriptions for asthma (controller or reliever 114 
medication) during 1 baseline year. Patients admitted to hospital with asthma as the primary 115 
diagnosis (ICD-10 code J45-J46) were eligible for the study if they had one or more valid blood 116 
eosinophil counts recorded during the year before the hospital admission with no prescription for 117 
oral corticosteroids within 2 weeks before the eosinophil count. 118 
 Eligible patients had to have available, continuous data throughout the study period (Fig 119 
1), which included ≥1 baseline year before discharge from the hospital for patient 120 
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characterization and ≥1 outcome year after hospital discharge for follow-up (except for patients 121 
who died within 1 year after hospital discharge). We included the first hospitalization recorded 122 
for each patient meeting those criteria. A diagnostic Read code for any of the following chronic 123 
respiratory conditions recorded at any time was cause for exclusion from the study: 124 
bronchiectasis, pulmonary sarcoidosis, hypersensitivity pneumonitis, malignancy of the lungs, 125 
interstitial lung disease, and cystic fibrosis. Patients with concomitant diagnosis of COPD were 126 
not excluded. 127 
 128 
Fig 1. Study Design. 129 
 130 
 The study was performed in compliance with all applicable local and international laws 131 
and regulations and to standards suggested for observational studies, including an independent 132 
advisory group, use of an a priori analysis plan, and study registration with commitment to 133 
publish [1618]. The study protocol was approved by the CPRD Independent Scientific Advisory 134 
Committee (ISAC approval number 16_236) and registered with the European Union electronic 135 
Register of Post-Authorisation Studies (EU PAS Register number EUPAS15869) [1719]. No 136 
patient identifying information was accessible during the study. 137 
 138 
Outcome assessments 139 
The exposure of interest was the most recent blood eosinophil count measured within 1 140 
year before hospital admission. For patients who had multiple tests in the baseline year, we used 141 
the blood eosinophil count (with no oral corticosteroid prescription within 2 weeks prior) that 142 
was closest to the admission. A high blood eosinophil count was defined as ≥0.35x109 cells/L (or 143 
≥0.4x109 cells/L when counts were recorded to only 1 decimal place). This value was chosen 144 
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based on our findings in a prior study in which patients with blood eosinophil counts >0.3x109 145 
cells/L experienced more severe exacerbations and poorer asthma control [3]. 146 
 The primary outcome was readmission to hospital with asthma as primary diagnosis 147 
(ICD-10 code J45/J46) over a 4-week outcome period and over a 1-year outcome period after 148 
discharge from the hospital (Fig 1). The secondary outcome was readmission to hospital with 149 
asthma as a secondary/subsidiary diagnosis and a respiratory condition as primary diagnosis 150 
(ICD-10 codes J00-J99), again observed over 4 weeks and 1 year. 151 
 152 
Statistical analysis 153 
Patients’ baseline characteristics and hospital readmissions were compared between 154 
patients with high and normal blood eosinophil counts using Pearson's χ2 test of independent 155 
categories for categorical variables, and the Mann-Whitney test for continuous variables.  156 
 Kaplan-Meier curves were constructed for patients with and without high blood 157 
eosinophil count for the maximum follow-up period of 1 year after hospital discharge. 158 
Comparisons were made with log-rank analyses, and patients were censored if they died.  159 
Cox proportional hazard regression, with the time from hospital discharge date to the first 160 
readmission date as the “survival” time, was performed to estimate hazard ratios (HRs) with 95% 161 
confidence intervals (CIs) for the association between high blood eosinophil count and time to 162 
readmission, adjusted for potential confounders. The following variables were evaluated for their 163 
potential confounding effect on the effect estimate: sex, age, body mass index (BMI), smoking 164 
habits, timing of blood eosinophil count relative to the first hospitalization, Charlson comorbidity 165 
index (categorical as 0, 1−4, ≥5), comorbidities, and Global Initiative for Asthma [1820] (GINA) 166 
treatment step (S1 Table). The likelihood of a blood eosinophil count being recorded was greater 167 
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at dates closer to the hospital admission, and we included the time between recorded eosinophil 168 
count and first hospitalization as a confounder in the Cox regression model. Final models were 169 
arrived at following a forward-selection procedure, in which variables were added one-by-one 170 
and retained if the coefficient for the effect estimate (high eosinophil count) changed by ≥5%. 171 
Co-linearity was checked by evaluating variance inflation factors, which were all under 5%. The 172 
validity of the proportional hazards assumption was checked by examination of survival curves, 173 
and p-values were calculated using a Wald test. 174 
 Potential effect modification of smoking status was tested for significance by including 175 
an interaction term into the full model. We conducted two several sensitivity analyses, repeating 176 
the outcome analyses using alternative definitions of high blood eosinophil counts (≥0.25x109 177 
cells/L or ≥0.3x109 cells/L if rounded, and ≥0.45x109 cells/L or ≥0.5x109 cells/L if rounded) and 178 
examining outcomes in a two subsets of patients: (1) after exclusion of those who initiated 179 
inhaled corticosteroids (ICS) after their first asthma-related hospital admission and (2) after 180 
exclusion of patients with a concomitant diagnosis of COPD. 181 
 Statistical analyses were conducted using IBM SPSS Statistics version 23 (IBM SPSS 182 
Statistics, Feltham, Middlesex, UK) and R version 3.0.2 (The R Project for Statistical 183 




Of 146,485 patients in the CPRD with HES data linkage, 22,940 (16%) patients had at 188 
least one hospital admission for asthma and ≥2 years of medical record data, and 3,611 patients 189 
(16%) of those hospitalized had an eosinophil count recorded within 1 year before the 190 
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hospitalization (and no oral corticosteroid prescription within 2 weeks prior). Of these 3,611 191 
patients, 2,613 patients (72%) were ≥5 years old, had active asthma, and were eligible for the 192 
study (Fig 2).  193 
 194 
Fig 2. Flow Diagram Showing Selection of Eligible Patients from the Database. 195 
CPRD = Clinical Practice Research Database. HES = Hospital Episode Statistics. OCS = oral 196 
corticosteroid. QOF = Quality Outcomes Framework. 197 
 198 
 In the study population, 482 of 2,613 patients (18%) were discharged from hospital on 199 
the same day. Six patients died (one patient died 31 weeks after readmission for asthma and was 200 
not censored; others were censored) during 1 year of follow up. 201 
 Characteristics of the total population with blood eosinophil count (n=2,613) and 202 
23 73113,016 patients with asthma who met all eligibility criteria except availability of blood 203 
eosinophil count during baseline are presented in S2 Table. There were multiple statistically 204 
significant differences between the two groups of patients. Eligible patients with recorded 205 
eosinophil count were older than the 23,73113,016 patients without eosinophil count (median 206 
age, 51 50 vs. 31 33 years), more commonly female (1,997/2,613, 76% vs. 207 
14,337/23,7317,542/13,016, 60%58%), heavier (mean BMI 29.229.1 vs. 26.526.0 kg/m2), and 208 
receiving a higher median ICS dose (262 219 vs. 164 132 µg/day, fluticasone-propionate 209 
equivalent) during the baseline year (S2 Table). 210 
 A high blood eosinophil count (≥0.35x109 cells/L) was recorded during the year before 211 
the hospital admission for 835 of 2,613 patients (32%). The high blood eosinophil cohort had a 212 
median age of 45 (vs. 54 years in the cohort with eosinophil count of <0.35x109 cells/L) and 213 
included proportionately fewer women and fewer overweight and obese patients (Table 1). In 214 
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addition, patients with eosinophil count ≥0.35x109 cells/L were more likely to be never-smokers 215 
and to have a recorded diagnosis of rhinitis, atopic eczema, or nasal polyps. 216 
 217 
  218 
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Table 1. Baseline Demographic and Clinical Characteristics. 219 
 
All patients 
(N = 2,613) 
Blood eosinophil cohort  
Variable 
<0.35x109 cells/L 
(n = 1,778) 
≥0.35x109 cells/L 
(n = 835) 
P valuea 
Age     
Median (IQR) 51.0 (36.0-69.0) 54.0 (39.0-70.3) 45.0 (30.0-65.0) <0.0001 
5-12 years 56 (2.1) 17 (1.0) 39 (4.7) <0.0001 
13-17 years 77 (2.9) 31 (1.7) 46 (5.5) 
18-64 years 1,681 (64.3) 1,141 (64.2) 540 (64.7) 
≥65 years 799 (30.6) 589 (33.1) 210 (25.1) 
Female sex  1,997 (75.7) 1,392 (78.3) 585 (70.1) <0.0001 
Smoking statusb      
Data available 2,597 (99.4) 1,771 (99.6) 826 (98.9)  
Current smoker 547 (21.1) 378 (21.3) 169 (20.5) 0.007 
Ex-smoker 754 (29.0) 544 (30.7) 210 (25.4) 
Never smoker 1,296 (49.9) 849 (47.9) 447 (54.1) 
Body mass indexb     
Data available 2,260 (86.5) 1,551 (87.2) 709 (84.9)  
Mean (SD) 29.2 (7.0) 29.6 (7.0) 28.4 (7.0) <0.0001 
<18.5 kg/m2 78 (3.5) 38 (2.5) 40 (5.6) <0.0001 
≥18.5 kg/m2 to <25 kg/m2 625 (27.7) 393 (25.3) 232 (32.7) 
≥25 kg/m2 to <30 kg/m2  625 (27.7) 450 (29.0) 175 (24.7) 
≥30 kg/m2  932 (41.2) 670 (43.2) 262 (37.0) 
Allergic/non-allergic rhinitisc 876 (33.5) 545 (30.7) 331 (39.6) <0.0001 
Atopic eczemac 927 (35.5) 595 (33.5) 332 (39.8) <0.0001 
Nasal polypsc 83 (3.2) 39 (2.2) 44 (5.3) <0.0001 
Chronic rhinosinusitisc 579 (22.2) 400 (22.5) 179 (21.4) 0.54 
COPDc 284 (10.9) 192 (10.8) 92 (11.0) 0.87 
GERDc 474 (18.1) 355 (20.0) 119 (14.3) <0.001 
Cardiovascular diseasec 654 (25.0) 491 (27.6) 163 (19.5) <0.0001 
Charlson comorbidity index     
0 611 (23.4) 429 (24.1) 182 (21.8) 0.028 
1-4 1,661 (63.6) 1,101 (61.9) 560 (67.1) 
≥5 341 (13.1) 248 (13.9) 93 (11.1) 
GINA step of asthma treatmentb     
1 124 (4.7) 78 (4.4) 46 (5.5) 0.009 
2 493 (18.9) 357 (20.1) 136 (16.3) 
3 468 (17.9) 298 (16.8) 170 (20.4) 
4 1,220 (46.7) 848 (47.7) 372 (44.6) 
5 308 (11.8) 197 (11.1) 111 (13.3) 
≥1 ICS inhaler prescribed 2,444 (93.5) 1,671 (94.0) 773 (92.6) 0.173 
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Daily dose of ICS (µg/day), 
median (IQR)d 
262 (110-521) 263 (110-534) 247 (99-492) 0.041 
≥1 SABA inhaler prescribed 2,432 (93.1) 1,646 (92.6) 786 (94.1) 0.144 
Daily SABA dose, median (IQR)d 1.64 (0.82-3.55) 1.64 (0.66-3.29) 2.04 (0.82-4.11) <0.0001 
OCS daily dose (g), median (IQR) 0.55 (0-1.64) 0.55 (0-1.56) 0.55 (0-1.75) 0.139 
No. severe asthma exacerbations     
0 747 (28.6) 516 (29.0) 231 (27.7) 0.25 
1 848 (32.5) 589 (33.1) 259 (31.0) 
2 506 (19.4) 345 (19.4) 161 (19.3) 
3 266 (10.2) 174 (9.8) 92 (11.0) 
≥4 246 (9.4) 154 (8.7) 92 (11.0) 
Data expressed as No. (%) unless otherwise noted. COPD = chronic obstructive pulmonary disease. GERD = 220 
gastroesophageal reflux disease. GINA = Global Initiative for Asthma; ICS = inhaled corticosteroid; OCS = oral 221 
corticosteroid; SABA = short-acting β-agonist.  222 
aP-value comparing blood eosinophil cohorts, computed from χ2 test for categorical variables, or Mann-Whitney test, 223 
for continuous variables. Where variables are presented as both continuous and categorical, the p-value is from the 224 
Mann-Whitney test. 225 
bThe closest BMI within 10 years of hospital discharge, and the smoking status closest to and within 5 years before 226 
hospital discharge, were included. The GINA treatment step was determined based on the last prescription before 227 
the hospitalization (S1 Table). The BMI categories applied to patients ≥18 years old; for children, BMI was not 228 
calculated because accurate information on age in months required to calculate BMI z-scores was not provided for 229 
privacy reasons. 230 
cComorbidities were those with diagnostic Read code ever-recorded in the available data before hospital discharge. 231 
dICS dose expressed as fluticasone propionate equivalent (µg/day), and one SABA dose defined as 200 µg in 232 
albuterol equivalents. 233 
 234 
 235 
The likelihood of a blood eosinophil count being recorded was greater at dates closer to 236 
the hospital admission (S1 Fig). Patients with measurements within 4 weeks before the 237 
hospitalization were more likely to have a high blood eosinophil count (128/339, 38%) than 238 
those with measurement within a longer time period before the hospitalization (707/2274, 31%; 239 
p=0.014). The length of time between recorded eosinophil count and admission with asthma as 240 
the primary diagnosis was greater in patients with high blood eosinophil counts than in patients 241 
without high counts, but the difference in distribution was not statistically significant (144 days 242 
[IQR, 56−250] vs. 131 days [58−229], p=0.159). 243 
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The median duration of hospitalization (2 nights) was the same in patients with and 244 
without a high blood eosinophil count; however, there were fewer patients with a high blood 245 
eosinophil count who had a long hospital stay (Table 2). 246 
 247 
Table 2. Duration of Hospitalization. 248 
 
All patients 
(N = 2,613) 
Blood eosinophil cohort  
Variable 
<0.35x109 cells/L 
(n = 1,778) 
≥0.35x109 
cells/L 
(n = 835) 
P valuea 
Nights in hospital, median (IQR)  2 (1–5) 2 (1–4)  
No. nights in hospital, n (%)     
0 482 (18.4) 323 (18.2) 159 (19.0) 0.006 
1 529 (20.2) 349 (19.6) 180 (21.6) 
2 356 (13.6) 230 (12.9) 126 (15.1) 
3 281 (10.8) 182 (10.2) 99 (11.9) 
4 243 (9.3) 162 (9.1) 81 (9.7) 
5 149 (5.7) 99 (5.6) 50 (6.0) 
6 142 (5.4) 106 (6.0) 36 (4.3) 
≥7 431 (16.5) 327 (18.4) 104 (12.5) 
aP-value comparing blood eosinophil cohorts computed from χ2 test. 249 
 250 
Readmissions by eosinophil cohort 251 
Only 6 patients were readmitted to the hospital within 4 weeks of the first admission, 252 
with no significant difference between blood eosinophil cohorts (Table 23). At 1 year, 130 of 253 
2,613 (5%) patients overall were readmitted for asthma, including a significantly greater 254 
percentage of patients with high vs. normal blood eosinophil count (Table 23; Fig 3). Patients 255 
with eosinophil count of ≥0.35x109 cells/L had a 45%49% higher adjusted risk of readmission to 256 
hospital for asthma in the first year of follow-up than patients without a high count (HR 257 
1.451.49; 95% CI 1.021.04–2.132.08; p=0.0400.029; Table 23). 258 
 259 
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Table 23. Readmissions to Hospital within 4 Weeks and 1 Year and Hazard Ratios for 260 
Readmission in the High Eosinophil Count Cohort. 261 





(n = 1,778) 
≥0.35x109 
cells/L 
(n = 835) 
P valuea 
Adjusted HR (95% 




With asthma as primary diagnosis 
(n = 2,613) 
   
  
Within 4 weeks 4 (0.2) 2 (0.2) 0.94 -- -- 





By known smoking status (n 
= 2,597)c 
     
















(n = 2,050) 





With respiratory condition other 
than asthma, and asthma as 
subsidiary diagnosis (n = 2,613) 
     
Within 4 weeks 22 (1.2) 8 (1.0) 0.53 --–– ---- 





aP-value computed using χ2 test. 262 
bAdjusted for sex, age, smoking status, timing of blood eosinophil count measurement, duration of index 263 
hospitalization. 264 
c16 patients with no recent record of smoking status were excluded from the analyses by smoking status.  265 
 266 
 267 
Fig 3. Kaplan-Meier Curves Describing the Cumulative “Survival” of a Readmission to 268 
Hospital for Asthma in the First Year After an Admission with Asthma as the Primary 269 
Diagnosis in Patients With and Without High Blood Eosinophil Count. 270 
 271 
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Interaction with smoking status 272 
There was significant The effect modification byof current smoking was non-significant 273 
(p=0.0440.073) when tested by including an interaction term for current smoking (yes/no) and 274 
high blood eosinophil count (yes/no) into the model. The increased readmission rate with a high 275 
blood eosinophil count was found only in non-smokers (HR 1.84; 1.211.20–2.80; p=0.0054) and 276 
not in current smokers (HR 0.810.88; 0.410.44–1.761.61; p=0.550.73). In this analysis of all 277 
2,613 patients, 16 patients without recent, recorded smoking status were included as non-278 
smokers (never-smokers plus ex-smokers).  279 
 Results were similar for patients with known smoking status, with a significant 280 
95%216% higher adjusted risk of readmission for never-smokers with high blood eosinophil 281 
count, and no additional risk for current smokers with high blood eosinophil count (Table 23). 282 
Although the association was most pronounced in never-smokers, no significant difference in the 283 
association was found between never-smokers and ex-smokers (p=0.800.67) in the 2,050 patients 284 
recorded as not currently smoking.  285 
 286 
Sensitivity analyses 287 
 A high blood eosinophil count was recorded for 1,328 patients (51%) when defined as 288 
≥0.25x109 cells/L, and for 588 patients (23%) when defined as ≥0.45x109 cells/L. The 289 
association between a high blood eosinophil count and readmission to hospital for asthma was 290 
less pronounced and not significant for patients with blood eosinophil count of either ≥0.25x109 291 
cells/L (HR=1.161.17; 0.82−1.661.65; p=0.390.41) or ≥0.45x109 cells/L (HR=1.121.15; 292 
0.750.77−1.721.69; p=0.500.57; S3 Table). The association was also not significant in never-293 
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smokers or in never/ex-smokers combined using either definition of high blood eosinophil count 294 
(S3 Table). 295 
 A total of 169 of the 2,613 patients (6%) had no prescription for ICS in the baseline year 296 
before being hospitalized for asthma; of the 169, 115 (68%) had ICS prescribed in the outcome 297 
year. After exclusion of these 115 patients, HRs for the association with blood eosinophil count 298 
of ≥0.35x109 cells/L slightly increased as compared with those for the full population (S3 Table). 299 
The HR was 1.761.77 (95% CI, 1.141.15−2.722.70; p=0.0090.010) for never/ex-smokers 300 
combined, which was very similar to the HR for never/ex-smokers combined of the full 301 
population (1.771.78). However, effect modification by current smokers was not significant in 302 
this subpopulation (p=0.28102). 303 
 Results of an additional subanalysis excluding patients with a concomitant diagnosis of 304 
COPD showed no relevant difference in association for the remaining 2,329 patients (HR= 1.48; 305 
95% CI 1.01–2.17, p=0.045; see S3 Table). 306 
 307 
Discussion 308 
In this large, historical cohort study, we found that patients who had a blood eosinophil 309 
count of ≥0.35x109 cells/L recorded in the year preceding an asthma-related hospitalization had a 310 
significantly greater risk of readmission for asthma during the year after they were discharged. 311 
Few patients (n=6) were readmitted to hospital for asthma within 4 weeks after discharge, while 312 
by 1 year after discharge, 5% (130 of 2,613) patients were readmitted for asthma. The greater 313 
risk of readmission during 1 year follow-up was present only for patients with high blood 314 
eosinophil count who were never- or ex-smokers (not for current smokers). 315 
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 Our study is one of few studies examining hospital readmissions for asthma in a general 316 
asthma population and in the real-life setting. Readmissions in the present study were 317 
comparatively infrequent relative to results in other studies: for example, in one US study, 318 
approximately 4% of patients were readmitted for an asthma exacerbation within 30 days [1921], 319 
and in France from 2002–2005, 15% were readmitted for asthma within 1 year [2022]. The 320 
overall rate of hospital admissions for asthma in England appears to be lower that than for 321 
Western Europe as a whole, the latter reported in 2004 to be 7% [1,23]. 322 
Other recent studies of hospital readmissions have been limited to patients on systemic 323 
corticosteroids [89], have examined readmissions up to only 30 days [10,1111,12,24,21], were 324 
much smaller [2124], and/or were conducted at a single institution [22,2325,26]. None of these 325 
studies, nor others examining readmissions after 30 days [24-2627-29], examined the association 326 
of hospital readmissions with blood eosinophil count. While Gonzalez-Barcala et al. [13] in their 327 
retrospective study at a single hospital in Spain found differently from the present study that 328 
elevated eosinophil count was associated with a lower incidence of readmissions, it is difficult to 329 
compare their study with ours because of differences in methods. For example, the reference 330 
blood eosinophil count was that taken upon admission rather than before hospitalization during a 331 
baseline year, and the length of the follow-up period for analyzing readmissions is unclear [13].  332 
 An interesting finding in the present study that requires further investigation is the effect 333 
of smoking status on association of readmissions with eosinophil count. Cigarette smoking 334 
increases levels of oxidative stress, alters airway immune responses, and increases risk of 335 
hospitalization in patients with asthma [2730]. Westerhof et al. [2831] in their study of patients 336 
with severe asthma found that frequent exacerbations were associated with blood eosinophil 337 
count only in never smokers and not in ex-smokers, for whom blood neutrophil count was an 338 
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independent predictor of frequent exacerbations (smokers not studied). In our study, both never- 339 
and ex-smokers (but not current smokers) who had a high eosinophil count were at greater risk of 340 
asthma-related readmission, although for ex-smokers separately this association was not 341 
statistically significant. Moreover, in our study the difference in association between non-342 
smokers (never-plus ex-smokers pooled) and smokers was large and statistically significant. 343 
Clearly, additional work is needed to examine biomarker and peripheral blood cell profiles in 344 
relation to smoking status and hospital readmissions and other asthma-related outcomes. 345 
 The median duration of hospitalization (2 nights) was the same in both normal and high 346 
blood eosinophil cohorts; however, patients with a high blood eosinophil count were less likely 347 
to have a hospital stay longer than 5 nights (17% vs. 24% of those without high eosinophil 348 
count). This finding illustrates the conundrum of eosinophilic asthma: while it tends to be more 349 
severe in terms of exacerbations and asthma control, eosinophilic asthma is also potentially more 350 
responsive to therapies targeting type 2 inflammation, including ICS and biologics. 351 
 We speculated that the association between eosinophil count and readmission could be 352 
diluted for patients with eosinophil count performed several months before the first admission; 353 
therefore, we re-examined outcomes including only patients with eosinophil counts measured 354 
close to the initial hospitalization to see if the association were stronger. However, when 355 
selecting those with eosinophil count recorded within 4 months before hospitalization, the 356 
numbers became small and associations non-significant, although the direction of the effect was 357 
the same: for never- and ex-smokers pooled (n=915), the risk of readmission was 51% greater 358 
but non-significant (adjusted HR 1.511.69; 0.540.60–4.764.25; p=0.3243). 359 
 A strength of this study is that we included a broad patient population with asthma, not 360 
limited to those with severe asthma. We selected inclusion criteria to ensure that patients’ asthma 361 
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was actively managed in advance of the hospital admission, thereby excluding patients 362 
experiencing a first episode of asthma diagnosed at the time of admission. Moreover, we 363 
required that patients had not received an oral corticosteroid prescription within 2 weeks before 364 
the eosinophil count to obviate the eosinopenic effects of systemic corticosteroids [29,3032,33]. 365 
The data sources we used are well-regarded and frequently employed for 366 
pharmacoepidemiological studies [13-1515-17,3134]. The primary care data in the CPRD is 367 
considered to be high-quality, with recording that has been standardized and improved since the 368 
institution in 2004 of the UK Quality Outcomes Framework (QOF) [1517], which provides 369 
financial incentives for GPs to deliver quality care, including an annual asthma review covering 370 
asthma control status, smoking, and inhaler technique. Detailed information about hospital 371 
admissions was drawn from HES, a data warehouse linked to the CPRD [1416].  372 
Nevertheless, a limitation is that the study dataset comprised information collected for 373 
clinical and routine use rather than specifically for research purposes. Moreover, prescriptions 374 
for drugs prescribed by specialists are not reliably recorded in the CPRD. Therefore, we could 375 
not evaluate treatment prescribed immediately after hospital discharge. However, the daily dose 376 
of ICS prescribed by GPs in the year after admission was not significantly different between 377 
patients with and without high eosinophil counts (median for both: 329 vs. 329 µg/day 378 
fluticasone-equivalent, p=0.70, Mann-Whitney test). Finally, as for all observational studies, 379 
there is the possibility of residual confounding from unrecognized and/or unmeasured factors. 380 
 A “count-response” association of blood eosinophil levels with risk of asthma 381 
exacerbations has been reported in both an observational study [3] and for the placebo arm of 382 
clinical trials [32,3335,36]. Our study had insufficient patient numbers to assess the presence of a 383 
count-response relationship with hospital readmissions using incremental categories to define 384 
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high eosinophil count. Our definition of ≥0.35x109 cells/L for high blood eosinophil count 385 
captured a clear association of high blood eosinophil count with risk of readmission, while there 386 
were fewer patients, hence limited statistical power, to evaluate the higher cut-point of ≥0.45x109 387 
cells/L, although the direction of the effect was the same. Alternatively, new ICS use or better 388 
ICS adherence after the index hospitalization might have reduced the effect of elevated 389 
eosinophil count; however, it would not be easy to quantify this possibility in the framework of a 390 
historical cohort study, and in spite of this possibility we found a strong association at the 391 
≥0.35x109 cells/L definition.  392 
We did not exclude patients with a concomitant diagnosis of COPD; therefore, 393 
approximately one-tenth of the study population appeared to have some form of physician-394 
diagnosed asthma-COPD overlap [3437], although these patients were too few to analyze 395 
separately. However, the sensitivity analysis excluding these patients supported the findings for 396 
the full population. 397 
 By necessity we were able to include only patients who had a recorded blood eosinophil 398 
count, which is not routinely measured in clinical practice, a factor serving as a possible source 399 
of selection bias and thereby limiting the generalizability of our findings. There were large 400 
differences in baseline characteristics between the patients with available eosinophil count and 401 
those without, who tended to be younger; more likely female, a current smoker, and of normal 402 
weight; and less likely having comorbidities such as rhinitis, chronic sinusitis, gastroesophageal 403 
reflux disease, and cardiovascular disease. The age differences were expected because older 404 
people more frequently have full blood counts available. Further work is needed to examine the 405 
use of blood eosinophil count in the clinical assessment of the full spectrum of patients with 406 
asthma.  407 
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 Tailoring asthma therapy using sputum eosinophil counts appears to be effective in 408 
reducing exacerbations, particularly for adults with frequent exacerbations [3538]. Thus, blood 409 
eosinophil count, more practical to measure than sputum eosinophil count, could play a role in 410 
tailoring asthma therapy with the goal of reducing exacerbations, hence potentially hospital 411 
readmissions. Moreover, further research is needed to identify the mechanism(s) behind the 412 
increased risk of readmission associated with high blood eosinophil count, such as possible 413 
undertreatment with ICS or insufficient effectiveness of ICS. In addition, more specifically, a re-414 
examination is needed of the absence of association with readmissions and high blood eosinophil 415 
count in current smokers, as there was limited statistical power in this subgroup of patients, 416 
reflected by the wide confidence interval. 417 
 418 
Conclusions  419 
A high blood eosinophil count in the year before an asthma-related hospitalization is 420 
associated with increased risk of readmission within the following year. This risk was slightly 421 
increased greater in the subset of patients who were not new initiators of ICS treatment after their 422 
index hospital admission, suggesting that this trait is only partially treatable with anti-423 
inflammatory therapy. This association was present only in non-smoking patients with high 424 
blood eosinophil count. Our findings support the benefit of including a full blood count with 425 
differential as a routine assessment in clinical practice for patients with not well-controlled 426 
asthma. Moreover, our findings support the need for careful follow-up, with treatment 427 
optimization, after hospital discharge for patients with asthma and preadmission high blood 428 
eosinophil count. 429 
  430 
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Review Comments to the Author 
 
Please use the space provided to explain your answers to the questions above. You may also 
include additional comments for the author, including concerns about dual publication, research 
ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 
characters) 
 
Reviewer #1: Thank you for conducting this retrospective review of admitted asthmatic patients. 
It was a pleasure to read. 
 
Response to Reviewer #1, Comment 1: Thank you very much for your review and the 
positive feedback. 
 
2. Could you please comment on the association between increased SABA use and decreased ICS 
dosages in the group with increased blood eosinophilia? What do you think this connection is? 
Your manuscript would be strengthened by exploring this in your Discussion. 
 
Response to Reviewer #1, Comment 2: We have additionally analyzed the correlation 
between average ICS and SABA daily dose and found a weak positive correlation, similar 
in patients both with and without high blood eosinophil count (Spearman’s rho, 0.31 and 
0.37, respectively). Therefore, from Table 1, we cannot conclude that decreased ICS use 
results in increased SABA use at the patient level. 
Although outside the scope of this manuscript, we can speculate about a reason for 
the slightly higher ICS doses in patients with low blood eosinophil count. Small effects of 
ICS on peripheral blood eosinophil counts may for example play a role. On the other 
hand, we know that high blood eosinophil counts are associated with more severe asthma, 
which could explain the greater use of SABA. This is the conundrum of eosinophilic 
asthma: it tends to be more severe in terms of exacerbations and asthma control but is also 
potentially more treatment responsive to T2 therapies including ICS and biologics. 
 
Reviewer #2: REVIEW: 18-12337: Association between blood eosinophil count and risk of 
readmission for patients with asthma: historical cohort study 
 
1. IMPORTANCE OF THE QUESTION OR SUBJECT STUDIED 
An understanding of prognosis of asthma based on blood eosinophils count is very interesting 
topic for research, which has not been fully explained so far. 
The objective is clearly stated. 
Mention in the introduction section of some references with contradictory results in asthma 
patients according to blood eosinophils count could be useful to explain the rationale for carrying 
out this study. There are some studies where higher blood eosinophil count is related to more 
hospital admissions (Mäkelä MJ, Eur Clin Respir J. 2018 Apr 15;5(1):1458560.), however other 
authors show us the contrary (Gonzalez-Barcala FJ, Eur J Intern Med. 2018 Mar 4. pii: S0953-
6205(18)30094-3.) 
 
Response to Reviewer #2, Comment 1: Thank you for alerting us to these new 
publications. We have added them to the Introduction as suggested. The variable 
associations may relate to the conundrum mentioned in our response to the first reviewer’s 
Response to Reviewers
second point, now included as an additional point in the Discussion (paragraph 5) with 
reference to the duration of hospitalization.  
 
ADEQUACY OF APPROACH 
In the methods section there are some weak points: 
1. It is stated that “patients with asthma who had been admitted to hospital in England”. 
However, the meaning of hospital admission is not clear. What should be clarified is whether 
admission includes emergency room, hospital ward, intensive care unit or all of them 
 
Response to Reviewer #2, Comment 1: We used the HES (Hospital Episode Statistics) 
Admitted Patient Care (APC) database, which contains records of patients who were 
admitted to a hospital ward, including patients who visited an emergency department 
before admission and patients who were admitted to an intensive care unit. We have now 
added this information to the Methods section. 
 
2. Patients were included “if they had one or more valid blood eosinophil counts recorded during 
the year before the hospital admission”. However, if the patients have more than one valid blood 
eosinophil count which one was considered: the higher, the smaller, the mean value, the more 
recent..? It should be clarified. 
 
Response to Reviewer #2, Comment 2: We used the most recent blood eosinophil count 
before the hospital admission, ie, closest to the admission, now clarified in the Methods 
section. 
 
3. It is stated that the timing of blood eosinophil count was considered, but it is not explained 
how it was done? 
 
Response to Reviewer #2, Comment 3: The likelihood of a blood eosinophil count being 
recorded was greater at dates closer to the hospital admission. We have now reported the 
median length of time between recorded eosinophil count and admission (with asthma as 
the primary diagnosis), which was greater in patients with high blood eosinophil counts 
than in patients without high counts, but the difference in distribution was not statistically 
significant (144 days [IQR, 56−250] vs. 131 [58−229], p=0.159). We included this 
variable as a confounder in the Cox regression model, as noted in the statistical analysis 
methods and in footnotes for Table 3 and S3 Table. 
 
4. In page 8, line 155, it is stated “Global Initiative for Asthma [18] (GINA) step”. I think that the 
words “of treatment” are necessary after step. 
 
Response to Reviewer #2, Comment 4: Thank you. We have now added “treatment” to 
GINA step wherever mentioned in the manuscript and supplemental information. 
 
5. The statistical treatment seems adequate 
6. Acceptable from an ethical point of view 
 
Response to Reviewer #2, Comments 5 and 6: Thank you. 
 
RESULTS 
The results are well presented. However there some weak points too: 
7. In table S2 there are data about the patients included and not included. Some statistical analysis 
to check the significance of the difference between these groups seems necessary 
 
Response to Reviewer #2, Comment 7: We have reworked S2 table, as we discovered 
upon doing the statistical comparisons that some patients were represented more than 
once in the excluded column (ie, for additional hospitalization episodes at older ages). 
Moreover, for this new table we have included baseline characteristics for all patients at 
the time of their first hospitalization, in line with the study analyses, to obtain better 
insights regarding differences in patient characteristics between included vs. excluded 
patients (with vs. without eosinophil count). (As noted in the Methods section, we 
included the first hospitalization episode for patients meeting eligibility criteria.) 
Therefore, we included the first hospital admission in the database for the 2,613 
patients eligible for the study, regardless of availability of eosinophil counts in the prior 
year. For 2,076 of these 2,613 patients (79%) this admission was the same as the 
admission analyzed and reported in the main paper. Instead, for 537 patients (21%), the 
baseline characteristics refer to those at their first recorded hospitalization, while a later 
admission (when they had a blood eosinophil count recorded during the prior year) was 
used for the main analyses. Hence there are differences between baseline characteristics 
for eligible patients as reported in Table 1 versus S2 Table. 
We have now added p-values to S2 Table and have noted that there were multiple 
statistically significant differences, summarized in the Results section, between included 
and excluded patients. The age differences were expected because older people more 
frequently have full blood counts available.  
 
8. There are some important data lacking: the duration of hospital stay is important for 
readmissions 
 
Response to Reviewer #2, Comment 8: Thank you for this important observation. Please 
see the hospitalization durations now added as a new Table 2. Although the median 
admission duration (2 nights) was the same in patients with and without a high eosinophil 
count, there were fewer patients with a long stay in hospital among those with a high 
blood eosinophil count. Adjustment for this variable in the analyses resulted in a slightly 
stronger association with risk of readmission (HR=1.49; 95% CI 1.04-2.13; p=0.029).  
We have revised Table 3 (formerly Table 2) and S3 Table, showing results 
adjusted for duration of the first hospitalization. 
 
9. … and treatment after hospital discharge is very important too 
 
Response to Reviewer #2, Comment 9: Prescriptions for drugs prescribed by specialists 
are not reliably recorded in the CPRD. Therefore, we cannot provide accurate information 
on treatment immediately after hospital discharge. However, the average daily dose of 
ICS prescribed by GPs in the year after admission was not significantly different between 
patients with and without high eosinophil counts (median for both: 329 vs 329 µg/day 
fluticasone-equivalent, p=0.70, Mann-Whitney test). 
 In our sensitivity analysis excluding patients who initiated ICS after hospital 
admission in the first year of follow-up, we found a slightly increased association of high 
blood eosinophils with readmissions. 
 We have included these points and the year-2 ICS doses in the Discussion section. 
 
10. In table 2 the analysis of readmissions is not adjusted by obesity. It could be relevant because 
the impact of obesity could be different in eosinophilic and non-eosinophilic asthma (Mukadam 
S1, , J Asthma. 2017 Aug 28:1-6) 
 
Response to Reviewer #2, Comment 10: We have evaluated confounding by BMI by 
including a variable with categories underweight, normal weight, overweight, or obesity 
into the Cox regression model and found no relevant (<2%) change in the coefficient for 
the association between a high eosinophil count and time to the first hospital admission. 
When including a dichotomous variable obesity (yes vs. no) there was only an 0.07% 
change in coefficient. The main analyses were therefore not adjusted by obesity or BMI. 
However, there was relevant confounding in the sensitivity analysis using a higher cut-






10. Considering that smokers are included and 31% are 65 years old or more, some doubts 
emerge about the possibility of inclusion of COPD patients. The accuracy of the diagnosis from 
primary care should be discussed. 
 
Response to Reviewer #2, Comment 10: We have now performed and added the results 
and discussion of an additional sensitivity analysis excluding patients with a concomitant 
COPD diagnosis. We found no relevant difference in association for the remaining 2,329 
patients: HR= 1.48; 95% CI 1.01–2.17, P=0.045, S3 Table). 
 
11. The significant differences between patients included and not included should be cited as a 
limitation, and as a possible source of inclusion bias. 
 
Response to Reviewer #2, Comment 11: This fact was indeed included in the Discussion 
as a factor limiting generalizability of study results, and we have now added the 
reviewer’s point that it could serve as a possible source of selection bias. 
 
12. The readmission rate is quite low. Could the authors explain, at least hypothetically the 
reason for this result?. Could it be due to some selection bias based on lack of accuracy of 
diagnosis?. Or could it be due to the inclusion of mild exacerbations treated in the emergency 
room which didn´t need hospital ward admission? 
 
Response to Reviewer #2, Comment 12: Our understanding is that hospitalization rates 
for asthma are generally lower in the UK than in other countries. We do not believe that 
readmission rates were low because of selection bias or other factors, because the HES 
data are considered to be reliable. 
By our calculations, the crude annual admission rate in England is approximately 
2.5%, including day cases. (This is calculated from the data presented in the first 
paragraph of the Introduction: “Approximately 83,000 hospital episodes (including 
inpatient, day-case, and intensive care episodes) were recorded as related to asthma in 
England in 2011-2012, representing approximately 3.3 million patients with clinician-
reported, diagnosed-and-treated asthma in England during that time.”) Instead, according 
to the earlier global Asthma Insights and Reality surveys (Rabe et al. JACI 2004; 114:40-
47), the hospitalization rate in western Europe is 7% and that in the US is 9%. 
We have expanded the section on rates of readmissions in the second paragraph of 
the Discussion accordingly. 
 
 
13. The conclusions are clear and supported by the data presented. 
 




14. The references are relevant and updated. I think there are a few references lacking 
 
Response to Reviewer #2, Comment 14: We have added the references suggested by the 
reviewer (new references 6 and 13) in addition to another reference (23) supporting the 
rates of hospitalization in Western Europe. 
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